Institute of Occupational and Social Medicine, RWTH Aachen University, Aachen, Germany.
Sleep Breath. 2012 Dec;16(4):1229-35. doi: 10.1007/s11325-011-0638-2. Epub 2011 Dec 27.
International guidelines recommend short- (SABA) or long-acting b-agonists for the prevention of bronchoconstriction after exercise (EIB) in patients with exercise-induced asthma (EIA). However, other drugs are still in discussion for the prevention of EIB. We investigated the efficacy of a combination of inhaled sodium cromoglycate and the β-mimetic drug reproterol versus inhaled reproterol alone and both versus inhaled placebo in subjects with exercise-induced asthma (EIA).
The study aimed to prove the preventive effect of a combination of 1-mg reproterol and 2-mg disodium cromoglycate (DSCG) and its single components vs. placebo, measuring the decrease of FEV1 after a standardized treadmill test in 11 patients with recorded EIA. The study medication was twice as high as those of drugs which are commercially available (e.g., Allergospasmin®, Aarane®).
The results revealed that the combination of reproterol and DSCG was significantly effective against a decrease of FEV1 after a standardized exercise challenge test (ECT) compared to placebo. The short-acting b-agonist reproterol alone had almost the same effectiveness as the combination of reproterol and DNCG. The difference between the combination with DNCG and reproterol alone was less than 10% and insignificant (p 0.48). DNCG alone did not show a difference in the effectiveness compared to placebo.
Prevention of EIA with the combination of reproterol and DSCG or with reproterol only is effective. An exclusive recommendation in favor of the combination cannot be given due to the low difference in the effectiveness versus reproterol alone. Due to the limited number of subjects and some probands showing protection under DSCG, it cannot be completely excluded that there is some preventive power of DSCG in individual cases.
国际指南建议在运动性哮喘（EIA）患者中，使用短效（SABA）或长效β-激动剂预防运动后支气管收缩（EIB）。然而，其他药物仍在讨论中，用于预防 EIB。我们研究了吸入色甘酸钠和β激动剂丙卡特罗联合与单独吸入丙卡特罗以及与吸入安慰剂相比，对运动性哮喘（EIA）患者的预防效果。
该研究旨在通过 11 例 EIA 记录患者的标准化跑步机测试后 FEV1 的下降，证明 1 毫克丙卡特罗和 2 毫克二钠色甘酸钠（DSCG）联合及其单一成分对安慰剂的预防作用。研究药物的剂量是市售药物（如 Allergospasmin®、Aarane®）的两倍。
结果表明，与安慰剂相比，丙卡特罗和 DSCG 的联合用药在标准化运动挑战测试（ECT）后对 FEV1 的下降具有显著的疗效。单独使用短效β激动剂丙卡特罗的疗效几乎与丙卡特罗和 DNCG 的联合用药相同。DNCG 与丙卡特罗联合用药与单独使用丙卡特罗的差异小于 10%，且无统计学意义（p>0.48）。DNCG 单独使用与安慰剂相比，疗效无差异。
丙卡特罗和 DSCG 联合或单独使用预防 EIA 有效。由于与单独使用丙卡特罗相比，其疗效差异较小，因此不能单独推荐该联合用药。由于受试者数量有限，且一些研究对象在 DSCG 下表现出保护作用，因此不能完全排除 DSCG 在某些情况下具有一定的预防作用。
